Market news

LOS ANGELES, September 17, 2026--Puma Biotechnology has initiated ALISCA®-Lung2, a Phase II trial of alisertib in combination with paclitaxel to treat advanced small cell lung cancer.

LOS ANGELES, September 09, 2026--On Sept. 14, 2026, Puma Biotechnology CEO Alan Auerbach will present a corporate overview at H.C. Wainwright's 28th Annual Global Investment Conf.

LOS ANGELES, September 03, 2026--Puma Biotechnology reported its inducement awards granted in August 2026, as required under Nasdaq Listing Rule 5635(c)(4).

Motley Fool Press Release.

Here at Zacks, our focus is on the proven Zacks Rank system, which emphasizes earnings estimates and estimate revisions to find great stocks. Nevertheless, we are always paying attention to the latest value, growth, and momentum trends to underscore strong picks.

Puma Biotechnology Inc (PBYI) posts $8.2 million GAAP net income, raises full-year revenue and profit outlook, and advances its alisertib clinical program.

LOS ANGELES, August 06, 2026--Puma Biotechnology will host a conference call beginning at 1:30 p.m. PT on Aug. 6, following release of its earnings results for 2Q-2026.

LOS ANGELES, August 05, 2026--Puma Biotechnology announced its inducement awards granted for July 2026, as required under Nasdaq Listing Rule 5635(c)(4).

LOS ANGELES, July 23, 2026--Puma Biotechnology will host a conference call at 1:30 p.m. PT on August 6, 2026, following release of its 2Q-2026 results.